Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Synairgen (SYNG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.45 +0.25    +4.03%
13:17:06 - Real-time Data. Currency in GBP ( Disclaimer )
  • Volume: 357,817
  • Bid/Ask: 5.68 / 6.50
  • Day's Range: 5.52 - 6.45
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B0381Z20 
SEDOL:  B0381Z2
Synairgen 6.45 +0.25 +4.03%

LON:SYNG Financials

 
This summary provides an overview of the most significant critical numbers from each of the Synairgen financial reports, including theSynairgen income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the LON:SYNG financials over time via breakdowns of their annual reports.

Synairgen plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was GBP 4.75 million compared to GBP 12.41 million a year ago. Basic loss per share from continuing operations was GBP 0.0236 compared to GBP 0.0616 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SYNG Income Statement & Profits

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM -47.36%
 Total Revenue  Net Income
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue
Gross Profit
Operating Income -3.15 -3.15 -7 -7
Net Income -2.62 -2.62 -6.2 -6.2

SYNG Balance Sheet

Quick Ratio MRQ 3.88
Current Ratio MRQ 6.77
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 23.53 23.53 29.54 29.54
Total Liabilities 3.25 3.25 4.63 4.63
Total Equity 20.28 20.28 24.92 24.92

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -0.02
Revenue/Share TTM -
Operating Cash Flow  23.63%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 0.768 0.768 -7.91 -7.91
Cash From Investing Activities -1.82 -1.82 0.008 0.008
Cash From Financing Activities 0 0 0 0
Net Change in Cash -1.05 -1.05 -7.9 -7.9
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SYNG Price Commentary

Write your thoughts about Synairgen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nicholas Aldam
Nicholas Aldam May 17, 2022 8:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.marketwatch.com/story/synairgen-shares-rise-on-positive-analysis-of-phase-3-covid-19-treatment-trial-271652687610
Sarah Froggatt
Sarah Froggatt May 16, 2022 10:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.synairgen.com/media/synairgen-presents-at-ats-2022
Nicholas Aldam
Nicholas Aldam May 16, 2022 8:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Presenting to the ATS today, also rumours for a takeover…
Nicholas Aldam
Nicholas Aldam Apr 26, 2022 8:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Though brief, interesting read and move in the right direction: https://www.synairgen.com/media/presentation-at-eccmid
Elliot dd
Elliot dd Apr 14, 2022 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New promosing drug on the market in the name of VERU. Short Synairgen under 10
Nicholas Aldam
Nicholas Aldam Mar 22, 2022 7:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Polygon position, Polygon Global Partners LLP 50,927,428 Ordinary shares (25.3%). Major shareholder, in at different levels, will they sell out, NOPE
Nicholas Aldam
Nicholas Aldam Mar 18, 2022 14:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why shouldnt there be a recovery? Polygon still have a major position and speaks volumes, IMO. On unpteen occasions i have said the company are not just covid related researches but also many lung related conditions are u der the microscope. Defo HOLD
Harry Carson
Harry Carson Mar 18, 2022 10:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
recovery?
Nicholas Aldam
Nicholas Aldam Mar 17, 2022 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Indeed, oops
Harry Carson
Harry Carson Mar 17, 2022 9:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
oops
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email